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Intraocular pressure-sensitive retinal ganglion cell degeneration is
a hallmark of glaucoma, the leading cause of irreversible blind-
ness. Here, we used RNA-sequencing and metabolomics to exam-
ine early glaucoma in DBA/2J mice. We demonstrate gene
expression changes that significantly impact pathways mediating
the metabolism and transport of glucose and pyruvate. Subse-
quent metabolic studies characterized an intraocular pressure
(IOP)-dependent decline in retinal pyruvate levels coupled to dys-
regulated glucose metabolism prior to detectable optic nerve de-
generation. Remarkably, retinal glucose levels were elevated
50-fold, consistent with decreased glycolysis but possibly including
glycogen mobilization and other metabolic changes. Oral supple-
mentation of the glycolytic product pyruvate strongly protected
from neurodegeneration in both rat and mouse models of glau-
coma. Investigating further, we detected mTOR activation at the
mechanistic nexus of neurodegeneration and metabolism.
Rapamycin-induced inhibition of mTOR robustly prevented glau-
comatous neurodegeneration, supporting a damaging role for
IOP-induced mTOR activation in perturbing metabolism and pro-
moting glaucoma. Together, these findings support the use of
treatments that limit metabolic disturbances and provide bioener-
getic support. Such treatments provide a readily translatable strat-
egy that warrants investigation in clinical trials.
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Glaucoma is a complex disease characterized by the pro-gressive dysfunction and loss of retinal ganglion cells
(RGCs). Age, genetics, and elevated intraocular pressure (IOP)
are major risk factors. Glaucoma affects ∼80 million people
worldwide and thus represents a considerable health and eco-
nomic burden (1). Although there are strategies to manage IOP,
they do not treat the neurodegenerative component of glau-
coma. Many patients are refractory to pressure-lowering medi-
cation or they progress to blindness despite low, managed IOPs.
Subsequently, >40% of treated glaucoma patients will go blind in
at least one eye (2), highlighting the therapeutic need for new
neuroprotective strategies. Although the factors that initiate
glaucomatous neurodegeneration remain to be elucidated, they
are unlikely to be unique to glaucoma (3, 4). As such, neuro-
protective strategies in glaucoma will likely translate to other
common age-related neurodegenerations, such as Alzheimer’s
disease, where progressive neuronal dysfunction followed by
axon loss is a defining feature.
Increasing evidence suggests that risk factors for glaucoma
conspire to reduce energy production in the retina and optic
nerve. Age- and intraocular pressure- dependent metabolic
deficits are emerging as a critical factor influencing RGC vul-
nerability in glaucoma (5, 6). RGCs sit on a metabolic knife edge
that is exacerbated by age and prolonged elevated IOP, and they
are dependent on neuronal mitochondria as well as glial trophic
support to maintain cellular homeostasis and bioenergetic needs.
Supporting a hypothesis in which bioenergetic insufficiency
renders RGCs susceptible to glaucomatous neurodegeneration,
mounting evidence suggests that mitochondrial and metabolic
disturbance are common in glaucoma patients, and strategies to
overcome or buffer these deficits have shown promise in cell and
animal models of glaucoma (5–8).
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Here, we demonstrate that by disturbing retinal glucose and
pyruvate levels, elevated IOP alters metabolism beyond the
changes caused by aging. Pyruvate is an important nutrient for
diverging energy metabolism pathways and for balancing energy
needs in different physiological contexts (9, 10). We find that
oral supplementation of pyruvate strongly protects from neuro-
degeneration in preclinical models of glaucoma. This study
provides important avenues for neuroprotection against glau-
coma by targeting key metabolic pathways.
Results and Discussion
To understand how elevated IOP alters energy metabolism in
RGCs in a chronic preclinical model of glaucoma, we analyzed
RNA-sequencing datasets from RGCs of 9-mo-old DBA/2J (D2)
and D2-Gpnmb+ mice (a strain-matched nonglaucoma control).
At 9 mo of age in our colony, D2 eyes have had ongoing high
IOP, but have not yet developed glaucoma, allowing for the as-
sessment of early predegenerative molecular changes. We fo-
cused on changes in energy metabolism defined by functional
analysis of differentially expressed genes. This identified many
early transcriptional changes to glycolysis (produces pyruvate),
mannose, and fructose metabolism, gluconeogenesis (utilizes
pyruvate), and pyruvate metabolism in general. Higher expres-
sion of pertinent regulatory genes also occurred in D2 RGCs,
including the glucose transporter Glut3, the glycolytic regulatory
gene Pfkfb3, pyruvate transporters Mpc1 andMpc2, and pyruvate
dehydrogenase component Pdha1 (SI Appendix, Fig. S1A). Given
the theme of altered pyruvate metabolism in the RGC gene
expression data, we next determined how retinal pyruvate levels
were affected. Pyruvate levels declined with increasing exposure
to elevated IOP in D2 retinas, but did not change significantly
with age alone (in control D2-Gpnmb+ mice) (SI Appendix, Fig.
S1 B and C). Thus, elevated IOP has a significant impact on
pyruvate production or metabolism. These data are consistent
with a genetic program in RGCs favoring pyruvate use in re-
sponse to chronically elevated IOP, or could indicate a loss in
pyruvate production during IOP-related stress (or a combination
of both). Since pyruvate is a key nutrient in various energy me-
tabolism pathways, pyruvate depletion may increase RGC dys-
function and vulnerability. Immunolabeling for mitochondrial
pyruvate carriers, MPC1 and MPC2, confirmed that RGCs have
the machinery to direct pyruvate into the citric acid cycle. These
proteins were present in high levels in RGCs across a range of
species (mouse, rat, primate, and human) (SI Appendix, Fig.
S1 D–G), and their transcript increased in RGCs following oc-
ular hypertension (SI Appendix, Fig. S H and I), highlighting the
potential importance of pyruvate metabolism to RGCs in healthy
and diseased states.
In addition to a major role in energy metabolism, pyruvate has
been shown to protect against PARP activation, oxidative stress,
and neuroinflammation (10, 11), all of which have been associ-
ated with glaucoma (12–15). We tested the ability of pyruvate to
protect stressed RGCs utilizing cultured retinal neurons and
assessing the effects of pyruvate treatment following glucose
deprivation or oxidative stress. In both models, pyruvate sup-
plementation enhanced neuronal survival (SI Appendix, Fig. S2).
Inhibiting monocarboxylate transporters, which facilitate pyru-
vate uptake into cells, with α-cyano-4-hydroxycinnamic acid
(4CIN) potently inhibited the protective action of pyruvate (SI
Appendix, Fig. S2). This suggests that pyruvate is an important
energy source and acts as a protectant for RGCs under stress.
The neuroprotective effects of pyruvate were also assessed in a
model of axon injury that leads to programmed cell death similar
to glaucoma. In mouse retina explant cultures pyruvate supple-
mentation prevented degeneration of axotomized RGCs (SI
Appendix, Fig. S3).
We further assessed the efficacy of long-term oral pyruvate
supplementation in vivo. In D2 eyes, IOP elevation is observed
beginning at 6 mo of age leading to significant optic nerve de-
generation, which typically occurs from 10 mo of age onwards.
This model is similar to human open angle glaucoma in that an
extended therapeutic window exists between the detection of
elevated IOP and progression of glaucomatous neuro-
degeneration. As such, we initiated pyruvate treatment at this 6-
mo-of-age time point, which would correspond to detection of
preglaucomatous ocular hypertension in human patients.
Pyruvate-treated D2 mice had increased levels of retinal pyru-
vate at 9 mo, an age prior to histologically detectable glaucoma
(Fig. 1A and SI Appendix, Fig. S4). Continued treatment reduced
the onset of optic nerve degeneration and prevented RGC loss at
older ages, yielding a decreased incidence of glaucoma (Fig. 1 B–
E). RGCs of aged, pyruvate-treated D2 mice had enhanced retinal
function compared to untreated mice (as assessed by pattern
electroretinography [PERG], a sensitive measure of RGC function
in humans and animals) and had intact, long-range axon projections
capable of anterograde axoplasmic transport (Fig. 1 F–I). As acute
or subacute high IOP insults contribute to clinical incidences of
glaucoma, we also tested pyruvate in an inducible model of glau-
coma. In this model, laser photocoagulation of limbal blood vessels
in rats induced a subacute elevation of IOP which leads to a sig-
nificant loss of RGCs. Pyruvate treatment increased RGC survival,
decreased RGC axon cytoskeletal damage, and decreased micro-
glial activation (Fig. 1 J–O). As pyruvate treatment protected from
neurodegeneration both in an interventional (explant axotomy) and
prophylactic setting (D2 glaucoma), pyruvate treatment has
promising potential to reduce glaucoma in patients with diverse
IOP and glaucoma-related insults.
To better understand the metabolic changes in glaucoma, we
performed metabolomics on single retinas at time points matching
our RNA-sequencing analysis. We analyzed D2-Gpnmb+ control
mice, untreated D2 mice, and D2 mice treated with pyruvate or
nicotinamide (NAM) (another metabolite we have demonstrated to
be strongly neuroprotective) (7). Eighty-six metabolites were iden-
tified at level 1 accuracy according to the Metabolomics Standards
Initiative (except for isoleucine) (16), the majority of which were
altered following elevated IOP (39 increased, 9 decreased in glau-
coma compared to controls) (Fig. 2 A–C and SI Appendix, Fig. S5
and Dataset S1). Pathway analyses of the altered metabolites
showed enrichment in pathways related to glucose metabolism and
oxidative stress, indicating a preponderance in changes related to
energy metabolism. Similar pathways were enriched in gene ex-
pression changes specific to RGCs (Fig. 2 D–F and Dataset S2).
These data suggest during ocular hypertensive stress there is met-
abolic coupling between RGCs and other retinal cell types and/or
that the observed changes in metabolites occur in RGCs. The
largest change in a single metabolite following elevated IOP was
glucose (52-fold increase). The increased glucose may reflect al-
tered glycolysis or other features of glucose metabolism, including
conversion of astrocytic glycogen (6). We previously demonstrated
PARP up-regulation in RGCs during D2 glaucoma and PARP can
inhibit glycolysis by impacting hexokinase (11). Elevated glucose is
associated with poor outcomes in brain injury and disease (17, 18),
and high glucose concentrations lead to decreased mitochondrial
cristae and mitochondrial remodeling in diabetic and cell models
(19, 20). D2 RGC mitochondria have decreased cristae at corre-
sponding disease time points (7). D2 mice do not have hypergly-
cemia (21, 22), implying that retinal glucose metabolism itself is
disrupted.
An additional key difference in metabolic profiles between
control and glaucoma retinas was a decrease in retinal NAM.
NAM levels were lower in D2 retinas compared to controls
consistent with decreased retinal nicotinamide adenine dinucle-
otide (NAD) levels in this model (7) and decreased serum NAM
levels in primary open angle glaucoma patients (23). We have
previously demonstrated that NAM confers a robust neuro-
protection against damaging IOP insults. NAM supplementation







































prevents age-dependent decreases in NAD levels, transcriptional
reprogramming of RGCs, mitochondrial decline, and RGC
neurodegeneration (5, 7, 24, 25). Unexpectedly, our metab-
olomic analysis of retinas from NAM-treated and untreated D2
mice did not detect differences outside of NAM itself. Pyruvate
treatment rescued more IOP-dependent changes in the retinal
metabolome than NAM. Pyruvate-treated D2 mice had differ-
ences in 27 metabolites compared to untreated mice, including
lower levels of glucose and higher levels of NAM (SI Appendix,
Fig. S6). As pyruvate was delivered orally, contributions from
metabolite changes due to enzymatic activity by the gut micro-
biome or in other tissues (e.g., liver, blood) are possible.
Pyruvate-induced changes in gut microbiome metabolism may
indirectly benefit against glaucoma. Nevertheless, in D2 mice,
oral pyruvate supplementation raises pyruvate levels in the retina
(Fig. 1A), suggesting that intact pyruvate reaches the target
tissues. Future experiments are needed to determine any roles of
the microbiome or systemic metabolism in this protection. Fu-
ture experiments could include the use of minipumps or local
delivery to avoid gut-based delivery and labeled pyruvate/isotope
tracers to identify the routes of pyruvate metabolism. There are
multiple mechanisms by which elevated pyruvate levels may lead
to an increase in NAM. One is a pyruvate-induced increase in
NAD availability to NAD-consuming enzymes that generate
NAM (e.g., PARPs and SIRTs; although pyruvate doesn’t di-
rectly produce NAD in these reactions) (26, 27). Alternatively,
pyruvate has been demonstrated to increase nicotinamide
phosphoribosyltransferase (NAMPT) levels in cancer cells (28).
NAMPT is a key enzyme in NAD synthesis by the salvage
pathway (29). Thus, pyruvate may modulate NAMPT to drive
NAD production; but these effects on NAMPT have yet to be
fully assessed in postmitotic neurons.
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Fig. 1. Pyruvate protects from glaucomatous neurodegeneration in chronic mouse and rat models. (A–I) DBA/2J mice. (A) Retinal pyruvate levels decline
following the onset of elevated IOP and are recovered by oral pyruvate treatment (n > 24/group). (B and H) Pyruvate intervention protected from optic nerve
degeneration as assessed by PPD staining (paraphenylenediamine; a sensitive stain for damaged axons) in D2 mice (n = 60/group). Green, no or early damage
(<5% axon loss; no or early [NOE]); yellow, moderate damage (∼30% axon loss [MOD]); red, severe (>50% axon loss [SEV]) damage. (C) Counts and (D) optic
nerve areas from D2 mice demonstrate a robust axon protection by pyruvate treatment (control = no glaucoma, D2-Gpnmb+; n = 10/group; all NOE except for
D2 which are SEV). (E and H) Pyruvate protected from RGC soma loss (RBPMS is a specific marker of RGCs in the retina; control = D2. Gpnmb+; n = 6/group). (F
and G) Pyruvate rescued PERG amplitude so that 12-mo-old treated mice were not significantly different from 9-mo-old untreated mice that had not yet
developed glaucomatous degeneration (PERG is a sensitive measure of RGC function in animals and humans; n > 20/group). Individual example tracings are
shown in G. (I) Pyruvate protects from the loss of anterograde axoplasmic transport as assessed by CT-β tracing to the dLGN (dorsal lateral geniculate nucleus)
and SC (superior colliculus) (control = D2-Gpnmb+; n = 6/group; quantification shown to the Right). (J–O) Inducible rat model. (J) Laser photocoagulation of
limbal blood vessels in rats caused a subacute elevation of IOP (ocular hypertension [OHT]). The magnitude of IOP elevation is unchanged by pyruvate
treatment. (K and L) Pyruvate treatment in the rat prevents RGC soma loss and axon loss in the optic nerve. Examples are shown in O. Brn3a is a specific
marker of RGCs in the rat retina. (M–O) Pyruvate treatment decreases RGC axon cytoskeletal damage (SMI32+ dystrophic axons) and decreases microglia
activation (ED1+ microglia) (n = 18/group for J–O). *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.
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Fig. 2. Retinal metabolic dysfunction occurs early following the onset of elevated IOP in D2 mice. (A) Whole retina samples underwent metabolomic
profiling (at 9 mo of age, n = 10/group, control = D2-Gpnmb+, glaucoma = D2). Hierarchical clustering (HC) (Spearman’s) defined metabolically distinct
groups. (B and C) A total of 86 metabolites were conclusively identified with level 1 accuracy according to the Metabolomics Standards Initiative (16) (except
for isoleucine) (39 increased, 9 decreased in D2 preglaucomatous retinas compared to controls). All metabolites are shown in B; significantly changed me-
tabolites are shown in C. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) and (E) The Small Molecule Pathway Database (SMPDB) pathway analysis of
metabolites demonstrates significant pathway enrichment of pathways related to glucose and pyruvate metabolism and NAD metabolism. Size of data point
represents number of metabolites in pathway. (F) A schematic pathway of glycolysis integrating metabolomic and RNA-sequencing data.







































In addition to providing an energy substrate for mitochondrial
respiration, pyruvate treatment affected NAD use. As NAD is a
critical factor for glycolysis, together a decrease in NAD and
pyruvate and an increase in glucose are consistent with a glyco-
lytic deficiency. During D2 glaucoma, RGC axons were recently
shown to have reduced capacity to increase glycolysis in response
to metabolic demand (30). Although the regulation of glycolysis
is complex, glycolytic insufficiency can occur if NAD levels de-
crease as the reduction of NAD+ to NADH is essential for
conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphogly-
cerate. Additionally, pyruvate metabolism is important for
replacing NAD+ (9). Thus, the reduced NAD and pyruvate
levels are likely to contribute to reduced glycolytic capacity in D2
RGCs, and vice versa. Another metabolite of interest for neu-
roprotection is gluconic acid. Levels of gluconic acid are in-
creased in the retina following ocular hypertensive stress
(Fig. 2B) and then further increased by pyruvate treatment (SI
Appendix, Fig. S6B). Gluconic acid is potentially produced by the
gut microbiome, especially following pyruvate treatment. It is an
antioxidant and modulates the pentose phosphate pathway and
hence glutathione metabolism, which is also changed by pyruvate
treatment (31, 32). Thus, gluconic acid may represent another
beneficial effect of this treatment.
Pyruvate and NAM are ideal treatments for clinical use, with
long histories and favorable safety profiles in humans (5, 33).
The most protective dose of NAM that we previously demon-
strated in D2 mice is large, complicating compliance, and may be
unachievable or unsafe in some patients (5, 7). Importantly, our
metabolomic data suggested that pyruvate and NAM treatments
may be complementary. Thus, supplementing the diet of D2
mice with both pyruvate and a suboptimal dose of NAM may be
beneficial. Combination therapy of pyruvate and NAM lowered
the risk of RGC loss and optic nerve degeneration in D2 mice by
∼2.6-fold, more than either treatment regime alone (SI Appen-
dix, Fig. S7). This combination therapy showed that targeting
IOP-dependent (declining pyruvate) and age-related (declining
NAD) changes in glaucoma can be additive and might represent
an ideal combination for human translation.
These metabolic and treatment data suggest that dysfunctional
metabolism may underlie RGC vulnerability in glaucoma. Re-
lated to this, pathway analysis of our RNA-sequencing data
predicted activation of the mTOR signaling pathway in RGCs in
ocular hypertensive eyes (Fig. 3 A and B). mTOR is a master
regulator of metabolism, and mTOR complex 1 (mTORC1)
modulates glucose use and glycolysis through Hif1α (34). Hif1α is
increased in the retinas of D2 mice following high IOP (7) and
D2 optic nerves have a decreased maximal respiratory rate and
altered glycolytic responses (30). Analysis of retinal proteins by
an mTOR pathway antibody array demonstrated a specific increase
in phospho-S6 and phospho-S6K, classic indicators of mTOR ac-
tivation (Fig. 3C). Further, immunofluorescence analysis demon-
strated activation of the mTOR pathway in retinal ganglion cells
and other cell types in aged D2 eyes (increased levels of phosphor-
mTOR (Ser-2448); Fig. 3D). The observed increase in mTOR
pathway activity corresponded with PARP activation (7) and in-
creased levels of glucose and related metabolites. Together, these
data collectively support an increase in neuronal energy use fol-
lowing IOP-related stress. As mTOR inhibition can protect neurons
from cell death by reducing energy use (35), we tested the role of
mTOR in D2 mice. D2 mice were treated with rapamycin to inhibit
mTOR-dependent metabolic reprogramming. Rapamycin is an
mTOR inhibitor that promotes survival mechanisms associated
with fasting and decreased energy use (34). Providing evidence that
mTOR and imbalanced energy regulation represent a critical target
for therapies, rapamycin treatment alone led to an ∼2.6-fold de-
crease in the incidence of severe glaucoma in D2 mice (Fig. 3 E–I
and SI Appendix, Fig. S4). These experiments support a role for
mTOR in glaucoma pathogenesis; however, as rapamycin’s effect is
not specific to mTORC1 (mTORC1 is implicated by the data in
Fig. 1C), further experiments are required to more precisely dissect
these pathways in the context of disease (36).
In conclusion, these findings are consistent with a model of
glaucoma where elevated IOP disrupts energy homeostasis by
affecting the availability of metabolic energy substrates. Further
affected by low availability of coenzymes, such as NAD+, RGCs
ultimately lack the energy needed to function and cope with
stress and inflammation associated with age and ocular hyper-
tension. Energy supplementation not only reduces degeneration,
but also improves visual function. In this light, decreased visual
function prior to degeneration may be an adaptive response to
reduce energy consumption and signal a need for energy sup-
plements. Although the combination of decreased NAD and
pyruvate represent a critical component of RGC susceptibility in
glaucoma, it is directly therapeutically approachable. Combining
vitamin and energy supplements with established IOP-lowering
therapies represents a powerful therapeutic strategy for human
glaucoma that necessitates clinical investigation.
Materials and Methods
Mouse Strains, Breeding, and Husbandry.Mice were housed in a 14-h light/10-h
dark cycle with food and water available ad libitum as previously reported
(7). All breeding and experimental procedures were undertaken in accor-
dance with the Association for Research for Vision and Ophthalmology
(ARVO) statement for the use of animals in ophthalmic research. The Insti-
tutional Biosafety Committee and the Animal Care and Use Committee at
The Jackson Laboratory approved this study. C57BL/6J (B6), DBA/2J (D2,
glaucoma), and DBA/2J-GpnmbR150X (D2-Gpnmb+, control) strains were uti-
lized. For aged glaucoma experiments mice were administered NAM, pyru-
vate, or rapamycin in water starting at 6 mo (prophylactic, prior to IOP
elevation in almost all eyes). NAM (550 mg/kg/d, PanReac AppliChem) and/or
pyruvate (500 mg/kg/d, Sigma) was dissolved in regular acid drinking water
(350 mL) and changed once per week. Rapamycin (Sigma) was administered
in drinking water at doses of 0.5 mg/kg/d and 2 mg/kg/d. Whole pens (n = 5
mice) were randomized between treatments and control.
Clinical Phenotyping. IOP elevation in D2 mice is subsequent to a pigment
dispersing iris disease. In all experiments, the progression of the iris disease
and intraocular pressure in mutant or drug-treated mice was compared to
control D2 mice as previously described (37). In each experiment, iris disease
and intraocular pressure were assessed. Iris disease was assessed at 2-mo
intervals starting at 6 mo of age until experiment completion. Intraocular
pressure was measured at 45-d intervals beginning at 8.5 to 9 mo until
experiment completion.
Rat Husbandry and Experimental Rat Glaucoma Models. Rat projects were
approved by the Animal Ethics Committee of the SA Pathology/Central
Adelaide Local Health Network (CALHN), Adelaide, and the University of
Adelaide, and conforms to the 2004 Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes. Adult Sprague-Dawley rats
(aged >10 wk, >230 g) were housed in a temperature- and humidity-
controlled room with 12-h light and dark cycles. Food and water were
provided ad libitum. Rats were randomly assigned into control (water only)
and pyruvate supplementation (500 mg/kg/day in normal drinking water)
groups. Rats were commenced on pyruvate supplementation exactly 1 wk
prior to glaucoma induction and continued on pyruvate throughout the
experiment. Animals were excluded from further analysis if severe hyphema
developed subsequent to laser treatment [29% collectively, which was lower
than the hyphema rate of 40% reported by Levkovitch-Verbin et al. (38)].
Experimental glaucomawas induced at day 0 in the right eye of all animals,
leaving the left eye untouched to serve as a control. A slightly modified
protocol of the method described by Levkovitch-Verbin et al. was used to
induce ocular hypertension in the right eye of each animal by laser photo-
coagulation of the episcleral and circumlimbal vessels (38). In brief, 135 to
150 spots of 100-μm diameter, 340 mW power, and 0.6-s duration were
applied to the circumlimbal vessels. An additional 35 to 50 spots, 200-μm
diameter, 300 mW power for 0.6-s duration, were delivered to the dominant
superior, inferior, and temporal episcleral veins while leaving the nasal
episcleral vein and intersecting nasal margins of the circumlimbal vessel
patent. Intraocular pressure was monitored using a rebound tonometer
(TonoLab, Icare).














































PERG. PERG was recorded subcutaneously (s.c.) from the snout of mice as
previously reported (7, 39). Waveforms were retrieved using an asynchro-
nous averaging method (40).
Optic Nerve Assessment and Determination of Glaucomatous Damage in DBA/
2J Mice. The processing of optic nerves and staining with paraphenylenedi-
amine (PPD) was as published (41). A segment of optic nerve from within a
region up to 1 mm from the posterior surface of the sclera was sectioned (1-
μm-thick sections) and stained with PPD. Typically 30 to 50 sections are taken
from each nerve. Multiple sections of each nerve were considered when
determining damage level. Optic nerves were analyzed and determined to
have one of three damage levels: NOE (no or early damage), MOD (mod-
erate damage), or SEV (severe damage) (7). Optic nerve axon counts were
performed using AxonJ (42).
Optic Nerve Assessment in a Rat Model of Experimental Glaucoma. A short
piece of proximal optic nerve from the right-treated eye of each rat, 1.5 mm
behind the globe, was removed for resin processing. In short, proximal optic
nerves were fixed by immersion in 2.5% glutaraldehyde with 4% parafor-
maldehyde in 0.1 M phosphate buffer, pH 7.4 for at least 24 h. Optic nerves
were then placed in osmium tetroxide in saline overnight and washed with
cocadylate buffer at room temperature (RT). Optic nerves were subsequently
dehydrated in graded alcohols and embedded in epoxy resin for transverse
sectioning. An ultramicrotome was used to cut sections at 1 μm, which were
then mounted on glass slides, and enhanced with osmium tetroxide-induced
myelin staining using 1% Toluidine Blue.
Histology: Optic Nerve Sections. For immunohistochemistry performed on
optic nerve sections, tissues were postfixed by immersion in 4% parafor-
maldehyde (PFA) at 4 °C overnight. Optic nerve and chiasma were then
processed for routine paraffin-embedded sections, embedded longitudi-
nally, and 5-μm sections were cut. Colorimetric immunohistochemistry was
performed as described above. Axonal injury was quantitatively assessed by
immunolabeling for SMI-32, an antibody which recognizes the non-
phosphorylated chain of neurofilament heavy. SMI-32 has been consistently
demonstrated to be a highly sensitive marker of axonal cytoskeleton dis-
ruption, owing to the labile nature of nonphosphorylated neurofilament
heavy chain and its susceptibility to degradation by calpain. Microglial status
was quantitatively assessed by immunolabeling for ED1. ED1 recognizes a
single chain glycoprotein that is expressed predominantly on the lysosomal
membrane of myeloid cells. The amount of ED1 expression can be correlated
to the extent of phagocytic activity. Quantification of immunolabeling for
each marker in longitudinal sections of the intracranial optic nerve was
performed as previously described (43). For each antigen, immunohisto-
chemistry was performed using one section of mid optic nerve and one
section of distal optic nerve adjacent to the optic decussation as previously
described. One photomicrograph from each location covering the entire
width of the nerve was taken using a 20× microscope objective. They un-
derwent color deconvolution to separate diaminobenzidine reaction prod-
uct from hematoxylin counterstain using ImageJ. Images were subsequently
analyzed with regard to the specifically stained area in pixels using
ImageJ. Measurements from one animal were averaged and treated as an
independent data point.
Anterograde Axon Transport. Mice were anesthetized using ketamine/xyla-
zine and intraviteally injected with 2 μL AF488 cholera toxin subunit B (CT-β;
1 mg/mL in phosphate buffered saline [PBS]) (Thermo Fisher Scientific). After
72 h, mice were anesthetized and killed via 4% PFA cardiac perfusion. Brains
and eyes were postfixed in 4% PFA for an additional 24 h, cryoprotected in
30% sucrose in PBS overnight, optimal cutting temperature compound
(OCT) cryoembedded, and sectioned at 20 μm. AF488 was visualized using a
Zeiss AxioObserver. Images were recorded at 20× at bregma −2.4 to −2.7




































































Fig. 3. mTOR activation occurs early in glaucoma with rapamycin treatment protecting from glaucoma. (A and B) Pathway analysis of RNA-sequencing data
from preglaucomatous D2 RGCs demonstrates significant enrichment of mTOR-related metabolic pathways. D2 groups 1 to 4 represent increasing disease
status at the transcriptomic level as identified in Williams et al. (7). Group 1 is indistinguishable from no glaucoma controls with no significant pathway
differences. (C) mTOR pathway antibody array demonstrated a specific increase in phospho-S6 and phospho-S6K, classic markers of mTOR activation. The two
labels for 4E-BP1 are separate phospho sites, Thr-36 and Thr-45. (D) Phospho-mTOR (Ser-2448) increases in GCL and IPL of D2 retinas (3.5 mo control vs. 9.5 mo
of age D2 shown; n = 7/group; see Materials and Methods). (E–I) Rapamycin intervention protected from optic nerve degeneration (PPD staining; n > 40/
group for E, n = 10/group for axon counts and measurements in F and G) and RGC soma loss (RBPMS labeling; n = 6/group). The most common class of nerve
for each group is analyzed in F and G with all being NOE except for D2 for which SEV nerves were analyzed. Control, unaffected NOE D2 nerves; D2, D2 water
control; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer. *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.







































colliculus [SC]) and whole CT-β for the tissue analyzed using the measure
intensity function (mean pixel intensity) in FIJI (ImageJ).
Histology: Whole-Mounted Retina and Retinal Sections (Immunofluorescence).
For immunofluorescence staining, mice were killed by cervical dislocation,
their eyes enucleated, and placed in 4% PFA overnight. Retinas were dis-
sected and whole-mounted onto slides, permeabilized with 0.1% Triton-X
for 15 min, blocked with 2% bovine serum albumin in PBS and incubated
overnight at RT in primary antibody (see SI Appendix, Table S1 for a com-
plete list of antibodies used in this manuscript). After primary antibody in-
cubation, retinas were washed five times in PBS and stained for 4 h at RT
with secondary antibody. Slides were then washed an additional five times
with PBS, labeled with 500 ng/mL DAPI for 15 min, mounted with fluo-
romount, and sealed with nail polish. For retinal sections, eyes were cry-
oprotected in 30% sucrose overnight, frozen in OCT, and cryosectioned at
18 μm. Slides were warmed to room temperature and the procedure above
was followed. Retinas were imaged on a Zeiss AxioObserver for low-
resolution counts.
For phospho-mTOR labeling in D2 mice, control (3.5 mo) and aged (9.5
mo) D2 eyes were enucleated and fixed in 4% PFA on ice for 3 h, followed by
cryoprotection with 30% sucrose, OCT embedding, and 10-μm sections were
cryosectioned. Slides containing both young and aged eye sections were
permeabilized and blocked with PBS, containing 0.5% Triton X-100 and 5%
donkey serum in room temperature for 30 min. Fluorescent stainings were
done in a three-step protocol using primary antibody overnight at 4 °C,
donkey anti-rabbit biotin (Invitrogen, A16027) 1 h at room temperature, and
streptavdin-549/DAPI for 1 h at room temperature, with washing by PBS
containing 0.5% Triton X-100 three times, 5 min after each step. Images
were captured on a Keyence BZ-810 microscope. Intensity of mTOR fluo-
rescent staining was quantified using FIJI. Briefly, the area encompassing the
inner plexiform layer (IPL) and ganglion cell layer (GCL) were outlined and
mean pixel intensity was recorded. Equal thresholding based on negative
control sections (secondary-antibody-only stained) was applied to the
background for all images. We compared staining between 15 young con-
trol and 15 aged eyes. Phospho-mTOR was increased in 7/15 of the aged eyes
with the others being indistinguishable from the controls. This is expected as
it is well established that some D2 eyes are molecularly unchanged, being
the same as nonglaucoma controls at 9.5 mo, while others have developed
early glaucoma with evident molecular changes (7). As molecular markers of
disease often enable improved comparions to controls and increased
phopsho-mTOR identifies eyes that have responded to IOP and are under-
going early glaucoma (as also evident by mTOR pathway changes by RNA-
sequencing), we compared the 7 responding eyes to 7 randomly selected
controls. Although confounded by eyes that have not yet changed, the
group difference was robust enough to be significant even when comparing
all 15 eyes in each group (P = 0.01).
Histology: Retinal Sections. Tissue sections from mouse, rat, marmoset, and
human donors were used to visualize mitochondrial pyruvate carrier ex-
pression. These studies were approved by the SA Pathology/CALHN Animal
Ethics Committee (Adelaide, Australia), and conformed with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013,
and with the ARVO statement for the use of animals in vision and ophthalmic
research. Ocular tissue was collected from adult marmosets (Callithrix jac-
chus), aged 10 to 14 y, belonging to the colony housed at the Queen Eliz-
abeth Hospital (South Australia, Australia) that were being killed. Human
ocular tissue for analysis was obtained from the Eye-Bank of South Australia,
Flinders Medical Centre (Adelaide, Australia) following the guidelines of the
Southern Adelaide Clinical Human Research Ethics Committee; all had been
screened to ensure there was no underlying ocular disease and all were from
Caucasian donors aged 50 to 65. There was no consistent orientation of globes
with regard to the nasal-temporal, superior-inferior quadrants of the retina
analyzed. Sections were typically taken at the level of the optic nerve head and
hence comprise at least two quadrants. Globes that were used for immuno-
histochemistry were immersion fixed in 10% buffered formalin or Davidson’s
solution for 24 h (rat and mouse) or 48 h (for marmoset and human eyes), and
transferred to 70% ethanol until processing. Eyes were then processed for
routine paraffin-embedded sections. Globes were embedded sagittally. In all
cases, 4-μm sections were cut. Colorimetric immunohistochemistry was per-
formed as previously described (44). In brief, tissue sections were deparaffi-
nized, endogenous peroxidase activity was blocked, and high-temperature
antigen retrieval was performed. Subsequently, sections were incubated in
primary antibody, followed by consecutive incubations with biotinylated sec-
ondary antibody and streptavidin-peroxidase conjugate. Color development
was achieved using 3,3′-diaminobenzidine. Confirmation of the specificity of
antibody labeling was judged by the morphology and distribution of the la-
beled cells, by the absence of signal when the primary antibody was replaced
by isotype/serum controls, and by the presence of a comparable signal when an
alternative primary antibody was used.
Mixed Retinal Cell Culture. Sprague-Dawley rats were housed according to
the Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes 2004, and the ARVO statement for the use of animals in ophthal-
mic and vision research. From stocks, litters of pups (1 to 3 d postpartum)
were obtained to derive mixed retinal cell cultures. Cultures were prepared via
a sequential trypsin- and mechanical-digest procedure and comprised neurons,
including RGCs, glia, and photoreceptors, as previously described (45). Isolated
cells were dispensed at 0.5 × 106 cells/mL onto 13-mm borosilicate glass cov-
erslips (precoated for 15 min with 10 μg/mL poly-L-lysine), for immunocyto-
chemistry, or into 96-well plates (CellPlus positive-charge-coated plates,
Sarstedt), for viability assays. Cultures were routinely maintained under satu-
rating humidity at 37 °C in minimum essential medium containing 10% (vol/vol)
fetal bovine serum (FBS), 5 mM D-glucose, 2 mM L-glutamine, and penicillin/
streptomycin.
For treatment of cell cultures, treatments were commenced at 7 d in vitro
and were carried out for 24 h. For nutrient deprivation (ND) experiments,
culture medium was replaced with one lacking FBS, glucose, pyruvate, and
glutamine. Pyruvate was added at appropriate test concentrations (100 μM, 1
mM, and 5 mM) and the monocarboxylate transport inhibitor, 4CIN, was
applied at 10 μM. For application of oxidative stress to cells, medium lacking
FBS, glucose, and pyruvate but containing 2 mM L-glutamine was used.
Glutamine was present in this case because removal of all nutrients caused
catastrophic death of all cells within 2 to 4 h and this amino acid has been
shown to support neuron survival in vitro (46). When cultures were to be
used for immunocytochemistry, cells on coverslips were fixed for 10 min with
10% (wt/vol) neutral buffered formalin containing 1% (vol/vol) methanol.
For viability assessment using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay, for the last hour of the incubation,
medium and test compounds were removed and new medium free of po-
tentially confounding dead cells/cell debris was applied along with 0.5 mg/
mL MTT. After 1 h, medium was removed from wells again and remaining
cells solubilized with dimethyl sulphoxide (DMSO) before colorimetric ab-
sorbance was determined at 570 nm (with 630-nm reference).
Immunocytochemical Assessment of Mixed Retinal Cultures. Fixed cells were
permeabilized in 0.1% Triton X-100 (vol/vol) in PBS for 15 min and then
blocked in 3.3% (vol/vol) horse serum in PBS (PBS-HS). Primary antibodies
were appropriately diluted in PBS-HS and applied to coverslips overnight at
room temperature in a moist chamber. After overnight incubation, cover-
slips were washed in PBS and then labeling was completed by successive
incubations with appropriate biotinylated secondary antibody (1:250) and
fluorescent Alexa Fluor-conjugated (488 or 594) streptavidin (1:500). Nuclear
counterstaining was achieved with a 5-min incubation between PBS washes
with 500 ng/mL DAPI. In the case of double labeling of cultures by two
antibodies, one was developed as mentioned and the other, concurrently,
with an appropriate secondary species-specific antibody directly linked to
the opposite colored Alexa Fluor fluorescent label. Quantification of im-
munocytochemistry was achieved by manually counting labeled cells for
each antibody in five fields per coverslip, averaging and rounding to the
nearest integer; this represented a single determination.
Whole Retina Explant Culture.Whole retina explant culture was performed as
previously described (7). Retinas were incubated in pyruvate in retinal ex-
plant media at the doses indicated. Retinas were incubated in six-well plates
at 37 °C and 4% CO2 for 5 d before being fixed in 4% PFA and stained with
DAPI. Retinas were imaged on a Zeiss AxioObserver.
Retinal Pyruvate Level Quantification. For pyruvate quantification, mice were
killed by cervical dislocation and retinas were homogenized in ice-cold Hanks’
balanced salt solution and pyruvate was measured following the manufac-
turer’s instructions (Cayman Chemical). Results were calculated according to
the standard curve generated by using standards from the kits. Final me-
tabolite concentrations for each sample were normalized to total protein
concentration measured by Bradford assay, and values are shown as percent
of young 4-mo-old mice of the respective genotype, as D2-Gpnmb+ mice had
lower values at all ages.
Metabolomics.
Reagents and chemicals. Liquid chromatography-mass spectrometry (LC-MS)
grade water was purchased from Honeywell (Riedel-de Haën; lot I174P) and














































formic acid was purchased from Sigma-Aldrich (lot 179247). LiChromasolv
hypergrade acetonitrile (lot 10947229817) and 2-propanol (lot
K50189881818) for LC-MS analysis were purchased from Sigma-Aldrich. The
internal lock masses (purine and HP-0921) and tune mix for calibrating the
quadrupole-time of flight mass spectrometry (Q-TOF-MS) (electrospray
ionization-low concentration tuning mix) were purchased from Agilent
Technologies.
Sample preparation. Samples (in 1.5-mL Eppendorf tubes) were kept on dry ice
while 150 μL of ice-cold methanol (Optima LC-MS, Fisher Scientific; lot
1862991) was added to each retina sample with a multichannel pipette.
Samples were vortexed for 15 s prior to sonication in an ice bath for 15 min.
Samples were then centrifuged at 12,000 × g for 12 min at 4 °C. Upon
completion, 140 μL of each sample supernatant was added to a separate
Ultrafree-MC VV Centrifugal Filter (Sigma-Aldrich; lot R7JA29961) and
centrifuged for 4 min at 8,000 × g at original temperature. The supernatant
(40 μL each) was transferred to two separate liquid chromatography (LC)
vials for zwitterionic hydrophilic interaction liquid chromatography
(ZIC-HILIC) and reversed phase analysis. Another 40 μL was collected from
each sample and pooled together to represent the quality control (QC). The
samples were randomized and after every batch of 12 samples a QC sample
was incorporated in order to observe any instrumental drifts, changes in
instrument sensitivity, as well as evaluate the % coefficient of variation (%
CV) of each detected metabolite.
Liquid chromatography-high resolution mass spectrometry (LC-HRMS)
experiments were performed on a 1290 Infinity II ultra-high performance
liquid chromatography (UHPLC) system coupled to a 6550 iFunnel Q-TOF
mass spectrometer equipped with a dual AJS electrospray ionization source
(Agilent Technologies). Polar metabolites were separated on a SeQuant ZIC-
HILIC (Merck) column 100 Å (100 mm × 2.1 mm, 3.5 μm particle size) coupled
to a guard column (20 mm × 2.1 mm, 3.5 μm particle size) and an inline filter.
Nonpolar metabolites were separated on an EclipsePlus C18 2.1 × 100 mm,
1.8 μm column, guard column (2.1 × 5 mm), and an inline filter. For the ZIC-
HILIC analysis, mobile phases consisted of 0.1% formic acid in water with
(solvent A) and 0.1% formic acid in acetonitrile with (solvent B). The elution
gradient used was as follows: isocratic step at 95% B for 1.5 min, 95% B to
40% B in 12 min, and maintained at 40% B for 2 min, then decreasing to
25% B at 14.2 min and maintained for 2.8 min, and then returned to initial
conditions over 1 min; the column was equilibrated at initial conditions for
7 min. The flow rate was 0.3 mL min−1, injection volume was 3 μL, and the
column oven was maintained at 25 °C. For the reversed phase (RP) analysis,
mobile phases consisted of 0.1% formic acid in water (solvent A) and 2-
propanol:acetonitrile (90:10, vol/vol) with 0.1% formic acid (solvent B). The
gradient elution was set as follows: isocratic step of 5% B for 3 min, 5 to 30%
B in 2 min, then B was increased to 98% in 13.5 min, maintained at 98% B
for 1.5 min, returned to initial conditions over 0.5 min, and then held for a
further 4.5 min. The flow rate was 0.4 mL/min, injection volume was 3 μL,
and the column oven was maintained at 50 °C. Two independent injections
were run for positive and negative acquisition modes. The Q-TOF MS system
was calibrated and tuned according to the protocols recommended by the
manufacturer. Nitrogen (purity >99.9990%) was used as a sheath gas and
drying gas at a flow of 8 L min−1 and 15 L min−1, respectively. The drying and
sheath gas temperature was set at 250 °C, with the nebulizer pressure at 35
psi and voltage 3,000 V (± for positive and negative ionization mode, re-
spectively). The fragmentor voltage was set at 380 V. The acquisition was
obtained with a mass range of 50 to 1,200 m/z, where full scan high-
resolution data were acquired at three alternating collision energies (0 eV,
10 eV, and 30 eV). The data acquisition rate was six scans sec−1. Between 16
and 25 min, LC flow was diverted to the waste for the ZIC-HILIC analysis. For
further details regarding the acquisition methodology, see Naz et al. (47)
and Daskalaki et al. (48). Positive and negative raw LC-HRMS files were in-
dependently processed with an in-house developed personal compound
database and library (PCDL) library for polar and nonpolar metabolites using
Profinder version B.06 (Agilent Technologies). Metabolites detected in both
ionization modes were correlated, and the ones with a larger relative in-
tensity as well as lower %CV were selected. Proper identification of reported
compounds (ZIC-HILIC = 52, reversed phase = 33) was assessed by accurate
mass and retention time (AMRT) plus fragment identification at two collision
energies (10 and 30 eV) using an in-house generated database. A separate
PCDL library was created to screen for isoleucine putatively. Metabolomics
data were analyzed using MetaboAnalyst and R using the 86 identified
metabolites as a background list for enrichment (49, 50). Metabolite iden-
tities were confirmed according to level 1 of the Metabolomics Standards
Initiative (16).
mTOR Phospho Antibody Array. mTOR phospho antibody arrays were per-
formed on n = 3 per condition of whole homogenized retina from 9 mo of
age D2 and D2-Gpnmb+ mice following the manufacturer’s instructions (Full
Moon BioSystems; PMT138). Data were analyzed in R using limma (linear
models for microarray data, designed for microarray analysis but suitable for
other data types) (51–53).
RNA-Sequencing. RNA-sequencing data were accessed through the Gene
Expression Omnibus (accession number GSE90654) and analyzed as previ-
ously described in R (7).
Statistics. The sample size (number of eyes, n) is shown in each figure legend.
Graphing and statistical analysis was performed in R. Student’s t test was
used for pairwise analysis in quantitative plots and Fisher’s exact test for
optic nerve analysis. Where multiple groups were compared, a one-way
ANOVA was employed, with a post hoc Tukey–Kramer test. For boxplots,
center hinge represents the median, the upper and lower hinges represent
the first and third quartiles, whiskers represent 1.5 × interquartile range,
and values beyond the whiskers are plotted as outliers. Unless otherwise
stated *P < 0.05, **P < 0.01, ***P < 0.001.
Data Availability. All study data are included in the article and supporting
information.
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